Syndax Pharmaceuticals, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Syndax Pharmaceuticals, Inc. (SNDX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $13.64 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-02-26
- Syndax Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $13.64, a 36.62% decline from fiscal 2024.
- Syndax Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $21.52, a 9.39% decline from fiscal 2023.
- Syndax Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $23.75, a 29.15% increase from fiscal 2022.
- Syndax Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $18.39, a 10.77% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|
| 2025-12-31 | $13.64 10-K · filed 2026-02-26 |
| 2024-12-31 | $21.52 10-K · filed 2025-03-03 |
| 2023-12-31 | $23.75 10-K · filed 2024-02-27 |
| 2022-12-31 | $18.39 10-K · filed 2023-02-28 |
| 2021-12-31 | $20.61 10-K · filed 2022-03-01 |
| 2020-12-31 | $11.91 10-K · filed 2021-03-12 |
| 2019-12-31 | $6.99 10-K · filed 2020-03-05 |
| 2018-12-31 | $9.37 10-K · filed 2019-03-07 |
| 2017-12-31 | $10.22 10-K · filed 2018-03-08 |
| 2016-12-31 | $12.64 10-K · filed 2017-03-14 |
| 2015-12-31 | $5.74 10-K · filed 2017-03-14 |
| 2014-12-31 | $8.92 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |